Next Article in Journal
Cross-Reaction or Co-Infection? Serological Discrimination of Antibodies Directed against Dugbe and Crimean-Congo Hemorrhagic Fever Orthonairovirus in Nigerian Cattle
Next Article in Special Issue
Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2
Previous Article in Journal
Viral RNA Metagenomics of Hyalomma Ticks Collected from Dromedary Camels in Makkah Province, Saudi Arabia
Previous Article in Special Issue
Potential Prophylactic Treatments for COVID-19

An Appraisal of the Current Scenario in Vaccine Research for COVID-19

Department of Molecular and Translational Science, Monash University, Clayton 3168, Australia
Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Kuala Lumpur 57000, Malaysia
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney 2007, Australia
School of Pharmacy and Pharmacology, University of Tasmania, Hobart 7005, Australia
Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida 201310, UP, India
School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston 7248, Australia
School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine BT52 1SA, UK
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Kenneth Lundstrom and Alaa A. A. Aljabali
Viruses 2021, 13(7), 1397;
Received: 4 June 2021 / Revised: 13 July 2021 / Accepted: 16 July 2021 / Published: 18 July 2021
(This article belongs to the Special Issue Vaccines and Therapeutics against Coronaviruses)
The recent coronavirus disease 2019 (COVID-19) outbreak has drawn global attention, affecting millions, disrupting economies and healthcare modalities. With its high infection rate, COVID-19 has caused a colossal health crisis worldwide. While information on the comprehensive nature of this infectious agent, SARS-CoV-2, still remains obscure, ongoing genomic studies have been successful in identifying its genomic sequence and the presenting antigen. These may serve as promising, potential therapeutic targets in the effective management of COVID-19. In an attempt to establish herd immunity, massive efforts have been directed and driven toward developing vaccines against the SARS-CoV-2 pathogen. This review, in this direction, is aimed at providing the current scenario and future perspectives in the development of vaccines against SARS-CoV-2. View Full-Text
Keywords: COVID-19; SARS-CoV-2; vaccines; therapeutic targets; immunity COVID-19; SARS-CoV-2; vaccines; therapeutic targets; immunity
Show Figures

Figure 1

MDPI and ACS Style

Chong, W.C.; Chellappan, D.K.; Shukla, S.D.; Peterson, G.M.; Patel, R.P.; Jha, N.K.; Eri, R.D.; Dua, K.; Tambuwala, M.M.; Shastri, M.D. An Appraisal of the Current Scenario in Vaccine Research for COVID-19. Viruses 2021, 13, 1397.

AMA Style

Chong WC, Chellappan DK, Shukla SD, Peterson GM, Patel RP, Jha NK, Eri RD, Dua K, Tambuwala MM, Shastri MD. An Appraisal of the Current Scenario in Vaccine Research for COVID-19. Viruses. 2021; 13(7):1397.

Chicago/Turabian Style

Chong, Wai C., Dinesh K. Chellappan, Shakti D. Shukla, Gregory M. Peterson, Rahul P. Patel, Niraj K. Jha, Rajaraman D. Eri, Kamal Dua, Murtaza M. Tambuwala, and Madhur D. Shastri 2021. "An Appraisal of the Current Scenario in Vaccine Research for COVID-19" Viruses 13, no. 7: 1397.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop